Validation of a model to assess long-term disease progression in Alzheimer's disease patients treated with rivastigmine

被引：0
|
作者：
Hauber, B
Candrilli, S
Snyder, EH
McBurney, CR
机构：
[1] Novartis Pharmaceut, E Hanover, NJ USA
[2] Res Triangle Inst, Chapel Hill, NC USA
来源：
NEUROBIOLOGY OF AGING | 2004年 / 25卷
关键词：
D O I：
10.1016/S0197-4580(04)80457-3
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
引用
收藏
页码：S136 / S136
页数：1
相关论文
共 50 条
  • [1] Long-term treatment with galantamine (Reminyl®) slows the disease progression of patients with Alzheimer's disease
    Hager, K
    Schwalen, S
    Schreiner, A
    Schmitt, A
    PROCEEDINGS OF THE 14TH ALZHEIMER EUROPEAN CONFERENCE, 2004, : 39 - 44
  • [2] Long-term progression of Alzheimer's disease in patients under antidementia drugs
    Gillette-Guyonnet, Sophie
    Andrieu, Sandrine
    Nourhashemi, Fati
    Gardette, Virginie
    Coley, Nicola
    Cantet, Christelle
    Gauthier, Serge
    Ousset, Pierre-Jean
    Vellas, Bruno
    ALZHEIMERS & DEMENTIA, 2011, 7 (06) : 579 - 592
  • [3] A-Beta Plasma levels and long-term response to rivastigmine in Alzheimer's disease
    Sobow, T.
    Flirski, M.
    Golanska, E.
    Liberski, P. P.
    Kloszewska, I.
    EUROPEAN PSYCHIATRY, 2008, 23 : S197 - S197
  • [4] Long-term effects of propentofylline in patients with Alzheimer's disease: Safety, efficacy, and impact on disease progression
    Rother, M
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1999, 47 (09) : S2 - S2
  • [5] Long-term treatment with galantamine in patients with Alzheimer's disease and Alzheimer's disease with cerebrovascular disease
    Feldman, H
    Van Baelen, B
    Brashear, HR
    Schwalen, S
    Kavanagh, S
    NEUROBIOLOGY OF AGING, 2004, 25 : S198 - S199
  • [6] The response of patients with Alzheimer's disease to rivastigmine treatment is predicted by the rate of disease progression
    Farlow, MR
    Hake, AM
    Messina, J
    Veach, J
    Anand, R
    NEUROLOGY, 2000, 54 (07) : A469 - A470
  • [7] The Impact of a Long-Term Rivastigmine and Donepezil Treatment on All-Cause Mortality in Patients With Alzheimer's Disease
    Kazmierski, Jakub
    Messini-Zachou, Chaido
    Gkioka, Mara
    Tsolaki, Magda
    AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS, 2018, 33 (06): : 385 - 393
  • [8] Mixture Disease Progression Model to Predict and Cluster the Long-Term Trajectory of Cognitive Decline in Alzheimer’s Disease
    Ryoichi Hanazawa
    Hiroyuki Sato
    Akihiro Hirakawa
    Therapeutic Innovation & Regulatory Science, 2025, 59 (2) : 264 - 277
  • [9] Consistent long-term efficacy of rivastigmine in mild, moderate and moderately severe Alzheimer's disease
    Kaufer, D.
    Quarg, P.
    Spiegel, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2004, 11 : 186 - 186
  • [10] Consistent long-term efficacy of rivastigmine in mild, moderate and moderately severe Alzheimer's disease
    Kaufer, D
    Quarg, P
    Spiegel, R
    NEUROBIOLOGY OF AGING, 2004, 25 : S101 - S101
12345